share_log

Aptar Expands Pharmaceutical Services; Announces Exclusive Collaboration Between Aptar Pharma And Fluidda

Aptar Expands Pharmaceutical Services; Announces Exclusive Collaboration Between Aptar Pharma And Fluidda

Aptar擴展製藥服務;宣佈Aptar Pharma和Fluidda之間的獨家合作
Benzinga Real-time News ·  2022/09/22 08:37
Nanopharm, an Aptar Pharma company and leader in contract research and development services for orally inhaled and nasal drug products (OINDPs), today announced an exclusive collaboration with Fluidda, a leader in the field of Functional Respiratory Imaging. The companies will leverage their respective proprietary technology platforms to help accelerate U.S. Food & Drug Administration (FDA) approvals for orally inhaled generic products (OIDPs) via the alternative bioequivalence pathway. Nanopharm was acquired by Aptar (NYSE:ATR) in 2019, as part of the company's strategy to expand its services offerings and partner with pharmaceutical companies earlier in the drug development process.
亞洲網加利福尼亞州聖何塞10月23日電Aptar製藥公司旗下口服吸入和鼻腔藥物產品(OINDPS)合同研發服務的領先者Nanopharm今天宣佈與功能呼吸成像領域的領先者Fluidda達成獨家合作。兩家公司將利用各自的專有技術平臺,通過替代生物等效性途徑,幫助加快美國食品和藥物管理局(FDA)對口服吸入型仿製藥(OIDP)的批准。納米藥業於2019年被Aptar(紐約證券交易所股票代碼:ATR)收購,這是該公司擴大服務範圍並在藥物開發過程中更早與製藥公司合作的戰略的一部分。
This...
這...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論